August 2017, Volume 3, Issue 10

August 2017

Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.

Table of Contents

August 2017 Issue

Musing on Medical Marvels

Tuesday, August 1st, 2017
It was circa 1999. I can picture the patient vividly: A mustachioed, unfailingly polite – but exhausted – middle-aged man holding a white tissue...

August 2017 Issue

Ned Sharpless Named New NCI Director, 2017 Pew-Stewart Cancer Research Scholars Announced, and more

Tuesday, August 1st, 2017
Norman Sharpless Named Director of the National Cancer Institute Norman “Ned” Sharpless, MD, has been appointed director of the National Cancer Institute (NCI) by President...

ASH Selects Outstanding Trainees for Award Programs, Honorific Award Winners, and more

Tuesday, August 1st, 2017
ASH Selects Outstanding Trainees for Award Programs 2017 ASH Research Training Award for Fellows ASH selected 11 fellows for the 2017 ASH Research Training Award for...

August 2017 Issue

Pulling Back the Curtain: Brady Stein, MD

Tuesday, August 1st, 2017
In this edition, Brady Stein, MD, talks about the overlap between teaching and practicing medicine, as well as passing down the tradition of hematology....

The Geography of Drug Approvals

Tuesday, August 1st, 2017
How can regulators look at the same data and get different results? The goal of regulatory bodies such as the U.S. Food and Drug Administration...

A Cure for Congress?

Tuesday, August 1st, 2017
An Interview With Jason Westin, MD As a hematologist and researcher, Jason Westin, MD, has dedicated his career to expanding and advancing treatment options for patients with...

August 2017 Issue

Hemophilia: Understanding Inhibitors

Tuesday, August 1st, 2017
Patients with hemophilia (a blood clotting disorder) can develop inhibitors (also called antibodies) when they have an immune response to factor concentrates (the treatment...

How would you treat a patient with aplastic anemia who refuses transfusions for religious...

Tuesday, August 1st, 2017
Here’s how readers responded to a You Make the Call question about a patient with aplastic anemia who refuses transfusions for religious reasons. Disclaimer: ASH...

How would you treat a patient with aplastic anemia who refuses transfusions for religious...

Tuesday, August 1st, 2017
This month, Neil A. Zakai, MD, discusses how to treat a patient with aplastic anemia who has religious objections to allogeneic blood product. And don't...

August 2017 Issue

Study Finds Low Incidence of Intracranial Bleeding With Preventive Low-Dose Aspirin

Tuesday, August 1st, 2017
The protective effect of low-dose aspirin against ischemic cardiovascular (CV) events and colorectal cancer (CRC) appears to outweigh the risks of major bleeding, including...

Randomized Study of Darbepoetin Alfa Shows Modest Reduction in RBC Transfusions in Patients With...

Tuesday, August 1st, 2017
Treatment with the erythropoiesis-stimulating agent (ESA) darbepoetin alfa can reduce the need for red blood cell (RBC) transfusions in patients with lower-risk myelodysplastic syndromes...

High-Dose Chemotherapy Plus Transplantation Improves PFS, But Not OS, in Myeloma Patients

Tuesday, August 1st, 2017
High-dose chemotherapy plus autologous hematopoietic cell transplantation (AHCT) has long been a standard treatment of multiple myeloma (MM), but the associated toxicity risks and...

NIH Will Not Cap Funding to Individual Laboratories

Tuesday, August 1st, 2017
The National Institutes of Health (NIH) is dropping its controversial proposal to limit grant funding to individual laboratories. The agency announced the plan in...

Pembrolizumab Trials Halt Enrollment After Patient Deaths

Tuesday, August 1st, 2017
The FDA placed a clinical hold on three trials evaluating the PD-1 inhibitor pembrolizumab in patients with multiple myeloma (MM) following reports of patient...

All Clinical Trials of Vadastuximab Talirine Suspended Following Patient Deaths

Tuesday, August 1st, 2017
Seattle Genetics, Inc., announced the discontinuation of the phase III CASCADE trial of vadastuximab talirine (also known as SGN-CD33A) in older patients with newly...

FDA Approves Rituximab and Hyaluronidase Combination for Several Lymphomas

Tuesday, August 1st, 2017
The U.S. Food and Drug Administration has approved the subcutaneous injection formula of rituximab and hyaluronidase for the treatment of adults with follicular lymphoma...

FDA Approves Betrixaban for Venous Thromboembolism

Tuesday, August 1st, 2017
The U.S. Food and Drug Administration (FDA) has approved betrixaban for the prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical...
WIB_icon

For Lenalidomide-Refractory Myeloma, Pomalidomide Is a Safe, Effective Secondline Option

Tuesday, August 1st, 2017
While it has become a standard to include lenalidomide in the frontline treatment of patients with multiple myeloma (MM), most patients have disease that...

Managing Toxicities of Dasatinib in Patients With CP-CML

Tuesday, August 1st, 2017
In randomized studies, the second-generation tyrosine kinase inhibitor dasatinib demonstrated deeper and more rapid major molecular responses (MRs) in patients with newly diagnosed chronic-phase...
WIB_icon

Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk CLL

Tuesday, August 1st, 2017
Ten-year follow-up data from the prospective phase II CLL3X trial of the German CLL Study Group confirms that patients with high-risk chronic lymphocytic leukemia...
WIB_icon

Managing GVHD Following HCT: New Uses for Old Treatments?

Tuesday, August 1st, 2017
Graft-versus-host disease (GVHD) remains a major complication following allogeneic hematopoietic cell transplantation (alloHCT) and, when severe, is associated with poor long-term overall survival. Two...

Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk CLL

Tuesday, August 1st, 2017
Ten-year follow-up data from the prospective phase II CLL3X trial of the German CLL Study Group confirms that patients with high-risk chronic lymphocytic leukemia...

August 2017 Issue

Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients...

Tuesday, August 1st, 2017
Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer who develop VTE may be at an increased risk...

Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL

Tuesday, August 1st, 2017
The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP), was able to be administered safely in patients...

Evaluating HCT Outcomes in Patients With Beta-Thalassemia

Tuesday, August 1st, 2017
Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at five years in patients with beta-thalassemia, when the transplant...

Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial

Tuesday, August 1st, 2017
Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results from the U.K. National Cancer Research Institute’s Myeloma XI...

Ropeginterferon Alfa-2B Versus Hydroxyurea in Patients With Polycythemia Vera

Tuesday, August 1st, 2017
Treatment with ropeginterferon alfa-2B, a mono-pegylated proline interferon, reduced JAK2 allele burden in patients with polycythemia vera (PV) and appeared to modify the underlying...

SHARE